RE:RE:RE:Conference Call Thanks BaystreetBrian, thedave2006, and MUGMODs for the update and information on GUD today.
Houndtrader: Based on the information we have, I believe EPS at $2.20 is from the priorty review voucher which they sold to Gilead Science for $125 million USD; source: https://www.gud-knight.com/en/knight-sells-priority-review-voucher-to-gilead
This one time lump some gain makes the earning per share at $2.20. However, keep in mind going forward it will most likely be less than this until Knight makes real revenue and acquisitions.
Right now I think it's a game of patience, sit and wait.
Knight invests over $40 million of secured loans in three separate transactions: Origin Biomed Inc., Apicore Inc. and CRH Medical Corporation. Gains from these transactions will show up later on if all goes well; source: https://www.gud-knight.com/en/knight-reports-fourth-quarter-and-year-ended-december-31-2014-results
I believe Goodman knows his stuff and is just waiting for the right time and good deals to come.
It's like Concordia Healthcare (CXR) they just recently made an acqusition for Covis Pharma announced on March 9, 2015. What seemed like an out of no where deal actually took months. On a BNN interview with Concordia CEO, Mark Thompson, he mentioned they were in business talks back in the beginning of the year January. The point is, deals take time, there are negotiations, etc.
As a retail investor, I say the strategy would be to "buy on weakness". So wait for the stock price of GUD to take dips and buy and accumulate shares then. Once you invested the amount you set out to invest in GUD, just be patient and wait. If this plays out like Paladin or even better, in a few years you should be reaping the rewards for your patience, money invested, and faith in Goodman and his team and company.
GUD luck all and cheers! =D
Knight has 400 million in cash reserves, and I believe Goodman is just waiting for the right deals and time.
We also have the initial investments in